Sodium Channel Blockers Failed Genetic Epilepsy for Decades. Relutrigine Took the State-Dependent Route.
Praxis Precision Medicines bypassed non-selective sodium channel toxicity in SCN2A and SCN8A DEEs by targeting persistent current. Now the FDA is examining its pivotal trial.
For decades, sodium channel blockers have been a first-line tool in epilepsy and a liability in the worst genetic forms of the disease. SCN2A and SCN8A developmental and epileptic encephalopathies are severe pediatric epilepsies marked by a pathologically increased persistent sodium current, frequent refractory seizures, profound neurodevelopmental arrest, and a high risk of sudden unexpected death in epilepsy. Drugs such as carbamazepine, phenytoin, and lamotrigine block the transient peak sodium current that initiates a normal action potential. That mechanism produces dose-limiting neurotoxicity, sedation, and ataxia, and in many of these patients it paradoxically exacerbates seizures.
Relutrigine (PRAX-562), an oral first-in-class small molecule functional state-selective sodium channel (NaV) modulator from Praxis Precision Medicines (NASDAQ: PRAX), was designed around that failure. The compound preferentially inhibits the persistent sodium current and high-frequency repetitive burst firing while relatively sparing peak physiological action potential conduction. The clinical question was whether that state-dependent selectivity would deliver seizure control without the class toxicity that has defined sodium channel blockade in DEE.
EMBOLD stopped early for efficacy
The pivotal answer came from EMBOLD (NCT05818553), a randomized, double-blind, placebo-controlled Phase 2/3 trial in children ages 1 to 18 with early-onset SCN2A or SCN8A DEE. Cohort 2 was stopped early for efficacy after an interim analysis and a Data Monitoring Committee recommendation, as Praxis later reported at AAN.
Patients received 1.0 mg/kg/day orally or via G/J tube. Over 16 weeks, Cohort 2 (51 on relutrigine, 25 on placebo) posted a 53% placebo-adjusted reduction in motor seizure frequency (p < 0.0002), following a 46% placebo-adjusted reduction (p = 0.0354) in Cohort 1. Motor seizure-free days rose 66.2% versus placebo (p = 0.034). Clinicians and caregivers also recorded greater than 25% placebo-adjusted gains on Clinical Global Impression and Caregiver Global Impression, with notable improvements in alertness and communication, domains that weigh as heavily as seizure counts in a population living with developmental arrest.
Tolerability tracked the underlying disease. Most treatment-emergent adverse events were mild to moderate. Pyrexia, upper respiratory infection, and somnolence were the most common. All serious adverse events were judged unrelated to study drug and consistent with background DEE morbidity. That profile is the operational test of the mechanism. Relutrigine suppressed pathological burst firing while leaving enough peak current for alertness and coordination.
Why the FDA moved the clock
The Food and Drug Administration accepted the New Drug Application under Priority Review in March 2026 and initially set a PDUFA target of September 27, 2026, according to a company release. Relutrigine already holds Breakthrough Therapy, Orphan Drug, and Rare Pediatric Disease designations, the last of which makes the program eligible for a Priority Review Voucher if approved.
On June 29, 2026, Praxis filed an 8-K stating that the agency had extended the PDUFA date by three months, to December 27, 2026. The trigger was additional sensitivity analyses of existing clinical data, which FDA classified as a "major amendment." No new trials were requested. The filing cited no safety, efficacy, or manufacturing concerns.
Subsequent review mechanics have been quiet. FDA completed the mid-cycle meeting with no major safety or efficacy concerns and confirmed that no advisory committee is planned. Bioresearch Monitoring inspections of Praxis operations produced zero Form FDA 483 observations, as the company noted in its second-quarter 2026 update. The extra quarter is statistical housekeeping on an early-stopped trial. The agency has identified neither a safety signal nor a failed endpoint.
A 5,000-patient start and a broader bet
The initial U.S. addressable population in SCN2A and SCN8A DEE is about 5,000 patients. Praxis is already running EMERALD, a Phase 3 study in broader DEEs spanning 50 genetic etiologies, with roughly 200 patients enrolled and topline data expected in the fourth quarter of 2026. If relutrigine's persistent-current selectivity holds outside SCN2A/8A, the commercial map expands from a rare-epilepsy niche into a platform claim across developmental epilepsies.
Praxis held .4 billion in cash, cash equivalents, and marketable securities as of June 30, 2026, with runway into 2028. The sharper tension is operational. Ulixacaltamide, a T-type calcium channel blocker for essential tremor, has a PDUFA date of January 29, 2027, one month after relutrigine's revised date. Two first-in-class neurology approvals a month apart would convert a clinical-stage company into a multi-product commercial enterprise almost overnight.
Conventional sodium channel blockade failed these children because it hit the wrong current. Relutrigine's 53% placebo-adjusted seizure reduction, the 66.2% gain in seizure-free days, and a clean BIMO record suggest the state-dependent route works. FDA is still examining how an early-stopped pivotal dataset should be sensitivity-tested. December 27 is when that review either becomes a label, a voucher, and the first of two commercial launches in a month, or it does not.